Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Follow-Up Questions
Who is the CEO of Ernexa Therapeutics Inc?
Mr. Sanjeev Luther is the President of Ernexa Therapeutics Inc, joining the firm since 2024.
What is the price performance of ERNA stock?
The current price of ERNA is $1.37, it has increased 7.87% in the last trading day.
What are the primary business themes or industries for Ernexa Therapeutics Inc?
Ernexa Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Ernexa Therapeutics Inc market cap?
Ernexa Therapeutics Inc's current market cap is $10.5M
